Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07018700 · ClinicalTrials.gov registry record · Phase 3

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

A Phase 3 study of Episodic Migraine, sponsored by Merz Therapeutics.

Recruiting
Registry status
Phase 3
Development phase
990
Enrollment target
20
Study locations

NCT07018700: Recruiting Phase 3 study of Episodic Migraine, sponsored by Merz Therapeutics.

NCT07018700 is a Phase 3 study of Episodic Migraine that is actively recruiting participants, run by Merz Therapeutics. The registered enrollment target is 990 participants, above the 420-participant average among 13 other Episodic Migraine trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07018700, a Phase 3 study of Episodic Migraine, is actively recruiting participants, sponsored by Merz Therapeutics.

RECRUITING
Registry status
Phase 3
Development phase
990 participants
Enrollment target
20
Study locations

Study Summary

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration: 52 to 55 weeks; * Screening period: 4 to 5 weeks; * Treatment duration: 4 treatments, each about 12 weeks apart; and * Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Conditions Studied

Episodic Migraine

Interventions

  • DRUG Placebo
  • DRUG Xeomin

Study Locations (20)

Florida

  • Northwest Florida Clinical Research Group, Merz Investigational Site #0010286 - Gulf Breeze
  • Nexus Clinical Research Center, Merz Investigational Site #0010514 - Homestead
  • Jacksonville Center for Clinical Research, Merz Investigational Site #0010515 - Jacksonville
  • Clinical Research of Central Florida, Merz Investigational Site #0010532 - Lakeland
  • American Research Institute, Merz Investigational Site #0010492 - Miami
  • Premiere Research Institute at Palm Beach Neurology, Merz Investigational Site #0010499 - West Palm Beach

California

  • Chemidox Clinical Trials Inc, Merz Investigational Site #0010488 - Lancaster
  • Clinical Research Institute, Merz Investigational Site #0010487 - Los Angeles
  • Clinical Trials Management Services, Merz Investigational Site #0010526 - Thousand Oaks
  • BNL Health Inc., Merz Investigational Site #0010489 - Torrance

Connecticut

  • Hasbani Neurology, Merz Investigational Site #0010509 - New Haven
  • Yale Center for Clinical Investigations, Merz Investigational Site #0010527 - New Haven
  • New England Institute Neurology and Headache, Merz Investigational Site #0010441 - Stamford

Arizona

  • TrialSphere Corp, Merz Investigational Site #0010513 - Chandler
  • Arizona Neuroscience Research, Merz Investigational Site #0010521 - Phoenix

Arkansas

  • Baptist Health Medical Center, Merz Investigational Site #0010520 - Little Rock

Georgia

  • Accel Research - NeuroStudies, Merz Investigational Site #0010523 - Decatur

Hawaii

  • Hawaii Pacific Neuroscience, Merz Investigational Site #0010510 - Honolulu

Kansas

  • Kansas Institute of Research,, Merz Investigational Site #0010495 - Overland Park

Trial Details

FieldValue
Enrollment Target 990 participants
Start Date 2025-08-21
Est. Completion 2027-10
Phase Phase 3
Merz Therapeutics

2 total trials

What NCT07018700 shows while recruiting

NCT07018700 is an interventional study that assigns participants to a tested intervention. The registered 990 participants enrollment target is mid-sized for trials with a published cap, above the 420-participant average among 13 other Episodic Migraine trials with a reported enrollment target (136% higher).

The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07018700 names 20 study sites across 9 states, led by Florida, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07018700 about?

NCT07018700 is a clinical study titled "A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine". In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections. Trial details include: * Trial duration...

What is the current status of trial NCT07018700?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 990 participants. The study started on 2025-08-21. Estimated completion is 2027-10.

What conditions does trial NCT07018700 study?

This clinical trial studies the following conditions: Episodic Migraine.

What interventions are being tested in trial NCT07018700?

The interventions under investigation include: Placebo (DRUG), Xeomin (DRUG).

Who is sponsoring clinical trial NCT07018700?

This trial is sponsored by Merz Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07018700 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Episodic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07018700's enrollment target sits among peer trials

990 1st of 13 higher than 13 of 13 other Episodic Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05441709 · 990 participants · NA

    Furthering Equity Through Infant Feeding EDucation and Support

  • NCT06340646 · 990 participants · NA

    Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

  • NCT06878261 · 990 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • NCT06883305 · 990 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07018700

Source: ClinicalTrials.gov NCT07018700, the US trial registry maintained by the National Library of Medicine. NCT07018700 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.